Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension von Rothwell, Peter M, Prof, Howard, Sally C, DPhil, Dolan, Eamon, MRCP, O'Brien, Eoin, Prof, Dobson, Joanna E, MSc, Dahlöf, Bjorn, Prof, Sever, Peter S, Prof, Poulter, Neil R, FMedSci

Volltext

Cognitive Function in a Randomized Trial of Evolocumab von Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R

Volltext

Inflammatory and Cholesterol Risk in the FOURIER Trial von Bohula, Erin A, Giugliano, Robert P, Leiter, Lawrence A, Verma, Subodh, Park, Jeong-Gun, Sever, Peter S, Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S

Volltext

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial von Charytan, David M, Sabatine, Marc S, Pedersen, Terje R, Im, KyungAh, Park, Jeong-Gun, Pineda, Armando Lira, Wasserman, Scott M, Deedwania, Prakash, Olsson, Anders G, Sever, Peter S, Keech, Anthony C, Giugliano, Robert P

Volltext

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke von Rothwell, Peter M, FMedSci, Howard, Sally C, DPhil, Dolan, Eamon, MRCP, O'Brien, Eoin, FRCP, Dobson, Joanna E, MSc, Dahlöf, Bjorn, MD, Poulter, Neil R, FMedSci, Sever, Peter S, FRCP

Volltext

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial von Sabatine, Marc S., MD, MPH, Giugliano, Robert P., MD, SM, Keech, Anthony, MD, Honarpour, Narimon, MD, PhD, Wang, Huei, PhD, Liu, Thomas, PhD, Wasserman, Scott M., MD, Scott, Robert, MD, Sever, Peter S., MD, Pedersen, Terje R., MD

Volltext

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism von Marston, Nicholas A., Gurmu, Yared, Melloni, Giorgio E.M., Bonaca, Marc, Gencer, Baris, Sever, Peter S., Pedersen, Terje R., Keech, Anthony C., Roselli, Carolina, Lubitz, Steven A., Ellinor, Patrick T., O’Donoghue, Michelle L., Giugliano, Robert P., Ruff, Christian T., Sabatine, Marc S.

Volltext

First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study von Davies, Justin E, Manisty, Charlotte H, Petraco, Ricardo, Barron, Anthony J, Unsworth, Beth, Mayet, Jamil, Hamady, Mohamad, Hughes, Alun D, Sever, Peter S, Sobotka, Paul A, Francis, Darrel P

Volltext

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials von Bangalore, Sripal, Dr, Kumar, Sunil, MD, Kjeldsen, Sverre E, Prof, Makani, Harikrishna, MD, Grossman, Ehud, Prof, Wetterslev, Jørn, MD, Gupta, Ajay K, MD, Sever, Peter S, Prof, Gluud, Christian, MD, Messerli, Franz H, Prof

Volltext

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK von Sever, Peter S., Chang, Choon L., Gupta, Ajay K., Whitehouse, Andrew, Poulter, Neil R.

Volltext

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With El... von Keech, Anthony C., Oyama, Kazuma, Sever, Peter S., Tang, Minao, Murphy, Sabina A., Hirayama, Atsushi, Lu, Chen, Tay, Leslie, Deedwania, Prakash C., Siu, Chung-Wah, Pineda, Armando Lira, Choi, Donghoon, Charng, Min-Ji, Amerena, John, Ahmad, Wan Azman Wan, Chopra, Vijay K., Pedersen, Terje R., Giugliano, Robert P., Sabatine, Marc S., on behalf of the FOURIER Study Group

Volltext

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-... von Poulter, Neil R, Wedel, Hans, Dahlöf, Björn, Sever, Peter S, Beevers, D Gareth, Caulfield, Mark, Kjeldsen, Sverre E, Kristinsson, Arni, McInnes, Gordon T, Mehlsen, Jesper, Nieminen, Markku, O'Brien, Eoin, Östergren, Jan, Pocock, Stuart

Volltext

Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the Relative Influ... von GUPTA, Ajay K, DAHLOF, Bjorn, DOBSON, Joanna, SEVER, Peter S, WEDEL, Hans, POULTER, N. R

Volltext

Clinical benefits of evolocumab appear less than hoped – Authors' reply von Giugliano, Robert P, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S

Volltext

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcom... von Bonaca, Marc P, Nault, Patrice, Giugliano, Robert P, Keech, Anthony C, Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A, Jukema, J Wouter, Lewis, Basil S, Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S

Volltext

Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial von CHAPMAN, Neil, CHANG, Choon Lan, DAHLÖF, Björn, SEVER, Peter S, WEDEL, Hans, POULTER, Neil R

Volltext

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial von O’Donoghue, Michelle L, Fazio, Sergio, Giugliano, Robert P, Stroes, Erik S.G, Kanevsky, Estella, Gouni-Berthold, Ioanna, Im, KyungAh, Lira Pineda, Armando, Wasserman, Scott M, Češka, Richard, Ezhov, Marat V, Jukema, J Wouter, Jensen, Henrik K, Tokgözoğlu, S Lale, Mach, François, Huber, Kurt, Sever, Peter S, Keech, Anthony C, Pedersen, Terje R, Sabatine, Marc S

Volltext

Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm von Mora, Samia, Chang, C. Lan, Moorthy, M. Vinayaga, Sever, Peter S

Volltext

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial von Giugliano, Robert P, Pedersen, Terje R, Park, Jeong-Gun, De Ferrari, Gaetano M, Gaciong, Zbigniew A, Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Ott, Brian R, Kanevsky, Estella, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M, Keech, Anthony C, Sever, Peter S, Sabatine, Marc S

Volltext

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis von Giugliano, Robert P., Pedersen, Terje R., Saver, Jeffrey L., Sever, Peter S., Keech, Anthony C., Bohula, Erin A., Murphy, Sabina A., Wasserman, Scott M., Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S.

Volltext